Last reviewed · How we verify
Low-dose CAN103
At a glance
| Generic name | Low-dose CAN103 |
|---|---|
| Sponsor | CANbridge (Suzhou) Bio-pharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-dose CAN103 CI brief — competitive landscape report
- Low-dose CAN103 updates RSS · CI watch RSS
- CANbridge (Suzhou) Bio-pharma Co., Ltd. portfolio CI